Class summary at a glance.

Every drug in the Antihypoglycemic Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $172.2Mcombined across class
Total Rx claims: 369K261K unique beneficiaries
Generic mfrs (active): 4across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Glucagon

Brand: Baqsimi · 361K Part D claims (CY24) · 255K beneficiaries · First FDA approval: 2015-05-08

4 generic mfrs 0 plans require PA

Low NADAC$197.69

→

Avg plan cost$225.70

Part D spend $168.7M 1× spread, current vs floor

Class share

98%

of class CY24 spend

View profile →

Dasiglucagon

Brand: Zegalogue · 8K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2023-06-26

Brand-only (no generics) 0 plans require PA

Low NADAC$492.83

→

Avg plan cost$493.95

Part D spend $3.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Glucagon Injection

Brand: Gvoke VialDx · — Part D claims (CY24) · First FDA approval: 2025-08-19

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Glucagon Injection, Solution

Brand: Gvoke HypoPen · — Part D claims (CY24) · First FDA approval: 2019-09-10

Brand-only (no generics) 0 plans require PA

Low NADAC$1600.03

→

Avg plan cost$1870.51

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.